中國利郎(01234.HK)2022年純利跌4.3%至4.48億元 毛利率提升至46.0%
格隆匯3月17日丨中國利郎(01234.HK)公佈2022年度業績,期內集團實現收入人民幣30.86億元,同比下降8.7%;毛利人民幣14.20億元,同比增長0.4%,毛利率由上年同期的41.9%增至46.0%;年度利潤人民幣4.48億元,同比下降4.3%;每股基本盈利人民幣37.42分,宣派末期股息每股9港仙及特別末期股息每股5港仙。
公吿稱,利潤下滑乃主要由於年內疫情重創線下零售業務,部份門店因應防控措施暫停營業,加上集團為分銷商提供返利,以致整體收入有所下跌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.